Stemedica Cell Technologies
- San Diego US-CA
Headquartered in San Diego and with offices in Lausanne and Singapore, Stemedica Cell Technologies, Inc., develops and manufactures allogeneic adult stem cells and stem cell factors that are employed in clinical and pre-clinical research studies. In July 2013, Stemedica announced that it had completed a Phase I study involving its lead product Stemedyne-MSC. As part of an investigation that evaluated the tolerability and safety of Stemedyne-MSC treatment, the adult ischemic allogeneic mesenchymal stem cells were used on ischemic stroke patients. With 15 patients taking part in the dose-escalation study, vital signs, adverse effects, and laboratory data were carefully observed. Throughout the inquiry, treatment was associated with improved functional speech and alertness, particularly in patients with significant injuries. An independent data safety monitoring board voted unanimously to advance trials to a Phase II study. A study co-investigator commented that Stemedyne-MSC cell therapy has the potential to significantly assist patients who have suffered cerebrovascular accidents with their recovery process.